Cost-effectiveness agency NICE has recommended NHS use of the therapy, called Kimmtrak (tebentafusp), for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal ...
but one of the conclusions of the pilot was that a pre-requisite for adoption will be "robust systems in place ensuring that the patient can easily access the package leaflet for their medicine in ...
The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. On December 3, 2024, IMCR announced that KIMMTRAK (tebentafusp) had been recommended for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback